ICER questions price of DMD therapies, reviews MS and depression drugs

Even under its more lax value assessment framework for rare diseases, the Institute for Clinical and Economic Review found that Duchenne muscular dystrophy therapies Emflaza deflazacort, Exondys 51 eteplirsen and golodirsen were not cost-effective. An ICER panel also weighed in on the institute's recent assessments of therapies for depression and multiple sclerosis.

In a draft evidence report released Wednesday,

Read the full 595 word article

User Sign In